
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

May 10, 2023

Commission File Number 001-35203

THERATECHNOLOGIES INC.

(Translation of registrant's name into English)

2015 Peel Street, Suite 1100
Montréal, Québec, Canada
H3A 1T8
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.

THERATECHNOLOGIES INC.

<u>Exhibit</u>	<u>Description</u>
99.1	Report on Voting Results Following the Annual Meeting of Shareholders Held on May 9, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond

Name: Jocelyn Lafond

Title: General Counsel and Corporate Secretary

Date: May 10, 2023



REPORT ON VOTING RESULTS
ANNUAL MEETING OF SHAREHOLDERS
HELD ON MAY 9, 2023

The Annual Meeting of Shareholders (the “**Meeting**”) of Theratechnologies was held online via a live audio/video webcast on Tuesday, May 9, 2023, at 10:00 a.m. (Eastern Time). Two (2) shareholders and/or proxy holders were present at the Meeting, in person or by proxy, holding 51,100,306 common shares of Theratechnologies, representing approximately 52.79% of the total votes attached to all issued and outstanding shares of Theratechnologies as of the record date on April 4, 2023.

Election of Directors

All nine directors proposed for election at the Meeting were elected by a vote conducted by ballot. All candidates were elected by a majority of the votes cast by shareholders present or represented by proxy at the Meeting. The directors will remain in office until the next annual meeting of shareholders or until their successors are elected or appointed. The proxies received by management for the election of directors were as follows:

	Votes For		Votes Withheld	
	#	%	#	%
Joseph Arena	23,138,582	73.03	8,545,048	26.97
Frank Holler	23,065,196	72.80	8,618,434	27.20
Gérald Lacoste	18,403,644	58.09	13,279,986	41.91
Paul Lévesque	23,077,346	72.84	8,606,284	27.16
Gary Littlejohn	18,569,960	58.61	13,113,670	41.39
Andrew Molson	22,847,163	72.11	8,836,467	27.89
Dawn Svoronos	22,723,149	71.72	8,960,481	28.28
Alain Trudeau	21,945,983	71.72	9,737,647	28.28
Dale Weil	22,847,453	72.11	8,836,177	27.89

Appointment of Auditors

The resolution to appoint KPMG LLP, chartered professional accountants, as Theratechnologies’ auditors to hold office until the next annual meeting of shareholders or until their successors are appointed, and to authorize the directors to fix their remuneration, was passed by a majority of the votes cast by ballot by the shareholders present or represented by proxy at the Meeting. The proxies received by management for the appointment of the auditors were as follows:

	Votes For		Votes Withheld	
	#	%	#	%
Auditors	46,921,922	91.82	4,178,384	8.18

Resolution 2023-1 Approving the Amendments to the Share Option Plan

Resolution 2023-1 approving the amendments to the share option plan was passed by a majority of the votes cast by ballot by the shareholders present or represented by proxy at the Meeting. The proxies received by management for the passing of resolution 2023-1 were as follows:

	Votes For		Votes Against		Votes Withheld	
	#	%	#	%	#	%
Resolution 2023-1	20,116,507	63.49	10,882,486	34.35	684,636	5.92